慢性乙型肝炎信号转导及转录激活因子3、5与Treg/Th17平衡的关系

李敏玥; 杨红菊; 李静; 宋瑞; 游晶

doi:10.3969/j.issn.1001-5256.2022.06.036

慢性乙型肝炎信号转导及转录激活因子3、5与Treg/Th17平衡的关系

DOI: 10.3969/j.issn.1001-5256.2022.06.036

李敏玥¹,
杨红菊¹,
李静²,
宋瑞¹,
游晶^1, , ,

1.
国家卫健委毒品依赖和戒治重点实验室，昆明医科大学第一附属医院老年消化内科，昆明 650032
2.
昆明医科大学公共卫生学院，昆明 650500

基金项目:

国家自然科学基金项目 (81760111);

国家自然科学基金项目 (81760617);

国家卫生健康委毒品依赖和戒治重点项目 (2020DAMARA-003)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李敏玥负责文献阅读及综述撰写；杨红菊、李静、宋瑞负责提供修改意见；游晶负责课题设计拟定写作思路，指导撰写、修改文章并最后定稿。

详细信息

通信作者:
游晶，jingyoukm@126.com

计量
- 文章访问数: 523
- HTML全文浏览量: 130
- PDF下载量: 33
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-26
- 录用日期: 2021-11-02
- 出版日期: 2022-06-20

Association of signal transducer and activator of transcription 3 and signal transducer and activator of transcription 5 with regulatory T cell/T helper 17 cell balance in chronic hepatitis B

Minyue LI¹,
Hongju YANG¹,
Jing LI²,
Rui SONG¹,
Jing YOU^{1
, ,
,}

1.
NHC Key Laboratory of Drug Addiction Medicine, Department of Geriatric Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
2.
School of Public Health, Kunming Medical University, Kunming 650500, China

More Information

Corresponding author: YOU Jing, jingyoukm@126.com(ORCID: 0000-0002-5919-5864)

摘要

摘要: 慢性乙型肝炎持续感染的免疫机制与T淋巴细胞密切相关，T淋巴细胞的发育需要多种细胞因子的协调作用，而信号转导及转录激活因子家族蛋白主要参与细胞因子的信号转导，尤其是STAT5a/b和STAT3在调节性T淋巴细胞(Treg)和辅助性T淋巴细胞17(Th17)的分化、发育过程中有着重要作用。本文主要就在慢性乙型肝炎中，对信号转导及转录激活因子3、5与Treg/Th17平衡的关系进行分析，研究HBV感染的慢性化及其引起的肝脏炎症调控机制。
- 乙型肝炎, 慢性 /
- STAT3转录因子 /
- STAT5转录因子 /
- T淋巴细胞, 调节性 /
- Th17细胞
Abstract: The immune mechanism of chronic hepatitis B (CHB) persistent infection is closely associated with T cells, and the development of T cells requires the coordination of a variety of cytokines. The proteins of the signal transducer and activator of transcription (STAT) family are mainly involved in the signal transduction of cytokines, and STAT5a/b and STAT3 play an important role in the differentiation and development of regulatory T cells (Treg) and T helper 17 cells (Th17). This article analyzes the association of STAT3 and STAT5 with Treg/Th17 balance in CHB and investigates the chronicity of hepatitis B virus infection and the regulatory mechanism of liver inflammation.
- Hepatitis B, Chronic /
- STAT3 Transcription Factor /
- STAT5 Transcription Factor /
- T-Lymphocytes, Regulatory /
- Th17 Cells

HTML全文

参考文献(55)

[1]	BURNS GS, THOMPSON AJ. Viral hepatitis B: clinical and epidemiological characteristics[J]. Cold Spring Harb Perspect Med, 2014, 4(12): a024935. DOI: 10.1101/cshperspect.a024935.
[2]	DONG Y, LI X, YU Y, et al. JAK/STAT signaling is involved in IL-35-induced inhibition of hepatitis B virus antigen-specific cytotoxic T cell exhaustion in chronic hepatitis B[J]. Life Sci, 2020, 252: 117663. DOI: 10.1016/j.lfs.2020.117663.
[3]	LIU B, GAO W, ZHANG L, et al. Th17/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B[J]. Int Immunopharmacol, 2017, 46: 48-55. DOI: 10.1016/j.intimp.2017.02.019.
[4]	NIU Y, LIU H, YIN D, et al. The balance between intrahepatic IL-17(+) T cells and Foxp3(+) regulatory T cells plays an important role in HBV-related end-stage liver disease[J]. BMC Immunol, 2011, 12: 47. DOI: 10.1186/1471-2172-12-47.
[5]	JIA GH, YOU J, LI J, et al. Role of Foxp3/Treg and RORγt/Th17 imbalance in chronic hepatitis B virus infection[J]. World Chin J Digestol, 2019, 27(11): 709-714. DOI: 10.11569/wcjd.v27.i11.709. 贾冠华, 游晶, 李静, 等. Foxp3/Treg与RORγt/Th17失衡在慢性乙型肝炎病毒感染中的作用[J]. 世界华人消化杂志, 2019, 27(11): 709-714. DOI: 10.11569/wcjd.v27.i11.709.
[6]	CAI Y, PAN L, LIN B, et al. Relationship between Treg/Th17 balance and changes in HBeAg among HBeAg-positive chronic hepatitis B patients receiving entecavir therapy[J]. Int J Virol, 2020, 27(5): 407-411. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.013. 蔡云, 潘良, 林斌, 等. 恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者外周血Treg/Th17平衡与HBeAg的变化[J]. 国际病毒学杂志, 2020, 27(5): 407-411. DOI: 10.3760/cma.j.issn.1673-4092.2020.05.013.
[7]	CHEN J, WANG L, FU Y, et al. The co-inhibitory pathway and cellular immune imbalance in the progress of HBV infection[J]. Hepatol Int, 2014, 8(1): 55-63. DOI: 10.1007/s12072-013-9464-x.
[8]	GAO B, WANG H, LAFDIL F, et al. STAT proteins - key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver[J]. J Hepatol, 2012, 57(2): 430-441. DOI: 10.1016/j.jhep.2012.01.029.
[9]	KONG X, HORIGUCHI N, MORI M, et al. Cytokines and STATs in liver fibrosis[J]. Front Physiol, 2012, 3: 69. DOI: 10.3389/fphys.2012.00069.
[10]	DING FM, LIAO RM, CHEN YQ, et al. Upregulation of SOCS3 in lung CD4⁺ T cells in a mouse model of chronic PA lung infection and suppression of Th17-mediated neutrophil recruitment in exogenous SOCS3 transfer in vitro[J]. Mol Med Rep, 2017, 16(1): 778-786. DOI: 10.3892/mmr.2017.6630.
[11]	JIANG Y, WANG X, DONG C. Molecular mechanisms of T helper 17 cell differentiation: Emerging roles for transcription cofactors[J]. Adv Immunol, 2019, 144: 121-153. DOI: 10.1016/bs.ai.2019.09.003.
[12]	DURANT L, WATFORD WT, RAMOS HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis[J]. Immunity, 2010, 32(5): 605-615. DOI: 10.1016/j.immuni.2010.05.003.
[13]	O'SHEA JJ, LAHESMAA R, VAHEDI G, et al. Genomic views of STAT function in CD4⁺ T helper cell differentiation[J]. Nat Rev Immunol, 2011, 11(4): 239-250. DOI: 10.1038/nri2958.
[14]	YANG XO, PANOPOULOS AD, NURIEVA R, et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells[J]. J Biol Chem, 2007, 282(13): 9358-9363. DOI: 10.1074/jbc.C600321200.
[15]	LIAO W, SCHONES DE, OH J, et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression[J]. Nat Immunol, 2008, 9(11): 1288-1296. DOI: 10.1038/ni.1656.
[16]	ZORN E, NELSON EA, MOHSENI M, et al. IL-2 regulates FOXP3 expression in human CD4⁺CD25⁺ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo[J]. Blood, 2006, 108(5): 1571-1579. DOI: 10.1182/blood-2006-02-004747.
[17]	HATZIOANNOU A, BOUMPAS A, PAPADOPOULOU M, et al. Regulatory T cells in autoimmunity and cancer: A duplicitous lifestyle[J]. Front Immunol, 2021, 12: 731947. DOI: 10.3389/fimmu.2021.731947.
[18]	SHATROVA AN, MITYUSHOVA EV, VASSILIEVA IO, et al. Time-dependent regulation of IL-2R α-Chain (CD25) expression by TCR signal strength and IL-2-Induced STAT5 signaling in activated human blood T lymphocytes[J]. PLoS One, 2016, 11(12): e0167215. DOI: 10.1371/journal.pone.0167215.
[19]	SOEHARSO P, SUMMERS KM, COOKSLEY WG. Allotype distribution of human T cell receptor beta and gamma chain genes in Caucasians, Asians and Australian aborigines: relevance to chronic hepatitis B[J]. Hum Genet, 1992, 89(1): 59-63. DOI: 10.1007/BF00207043.
[20]	YAO Z, CUI Y, WATFORD WT, et al. Stat5a/b are essential for normal lymphoid development and differentiation[J]. Proc Natl Acad Sci U S A, 2006, 103(4): 1000-1005. DOI: 10.1073/pnas.0507350103.
[21]	LAURENCE A, TATO CM, DAVIDSON TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation[J]. Immunity, 2007, 26(3): 371-381. DOI: 10.1016/j.immuni.2007.02.009.
[22]	PANDIYAN P, YANG XP, SARAVANAMUTHU SS, et al. The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes[J]. J Immunol, 2012, 189(9): 4237-4246. DOI: 10.4049/jimmunol.1201476.
[23]	YANG XP, GHORESCHI K, STEWARD-THARP SM, et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5[J]. Nat Immunol, 2011, 12(3): 247-254. DOI: 10.1038/ni.1995.
[24]	LIU C, XU L, XIA C, et al. Increased proportion of functional subpopulations in circulating regulatory T cells in patients with chronic hepatitis B[J]. Hepatol Res, 2020, 50(4): 439-452. DOI: 10.1111/hepr.13472.
[25]	FENG C, CAO LJ, SONG HF, et al. Expression of PD-L1 on CD4⁺CD25⁺Foxp3⁺ regulatory T cells of patients with chronic HBV infection and its correlation with clinical parameters[J]. Viral Immunol, 2015, 28(8): 418-424. DOI: 10.1089/vim.2015.0062.
[26]	COLLISON LW, CHATURVEDI V, HENDERSON AL, et al. IL-35-mediated induction of a potent regulatory T cell population[J]. Nat Immunol, 2010, 11(12): 1093-1101. DOI: 10.1038/ni.1952.
[27]	PARFIENIUK-KOWERDA A, JAROSZEWICZ J, FLISIAK R. Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection[J]. Clin Exp Hepatol, 2015, 1(2): 35-38. DOI: 10.5114/ceh.2015.51805.
[28]	YANG L, HU XQ, FU WZ. Correlation of peripheral blood Th17 cell surface CCR4, CCR6 and CXCR3 expression with the illness in patients with chronic hepatitis B[J]. J Hainan Med Univ, 2017, 23(11): 1478-1480, 1484. DOI: 10.13210/j.cnki.jhmu.20170607.002. 杨丽, 胡晓勤, 付万智. 外周血Th17细胞表面CCR4、CCR6、CXCR3表达量与慢性乙型肝炎患者病情的相关性[J]. 海南医学院学报, 2017, 23(11): 1478-1480, 1484. DOI: 10.13210/j.cnki.jhmu.20170607.002.
[29]	VELDHOEN M, HOCKING RJ, ATKINS CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells[J]. Immunity, 2006, 24(2): 179-189. DOI: 10.1016/j.immuni.2006.01.001.
[30]	LIU B, GAO W, ZHANG L, et al. Th17/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis B[J]. Int Immunopharmacol, 2017, 46: 48-55. DOI: 10.1016/j.intimp.2017.02.019.
[31]	KHOURIEH J, RAO G, HABIB T, et al. A deep intronic splice mutation of STAT3 underlies hyper IgE syndrome by negative dominance[J]. Proc Natl Acad Sci U S A, 2019, 116(33): 16463-16472. DOI: 10.1073/pnas.1901409116.
[32]	TANG Y, TAN SA, IQBAL A, et al. STAT3 genotypic variant rs744166 and increased tyrosine phosphorylation of STAT3 in IL-23 responsive innate lymphoid cells during pathogenesis of crohn's disease[J]. J Immunol Res, 2019, 2019: 9406146. DOI: 10.1155/2019/9406146.
[33]	DAVIDSON SI, LIU Y, DANOY PA, et al. Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese[J]. Ann Rheum Dis, 2011, 70(2): 289-292. DOI: 10.1136/ard.2010.133322.
[34]	FOSHAY KM, GALLICANO GI. miR-17 family miRNAs are expressed during early mammalian development and regulate stem cell differentiation[J]. Dev Biol, 2009, 326(2): 431-443. DOI: 10.1016/j.ydbio.2008.11.016.
[35]	FAN JJ, CHANG CF, WANG H. Association of single-nucleotide polymorphisms of STAT3and STAT4 with hepatocellular carcinoma[J]. J Pract Med, 2018, 34(21): 3593-3597, 3602. DOI: 10.3969/j.issn.1006-5725.2018.21.025. 范敬静, 常彩芳, 王浩. STAT3和STAT4基因单核苷酸多态性与肝细胞癌的相关性[J]. 实用医学杂志, 2018, 34(21): 3593-3597, 3602. DOI: 10.3969/j.issn.1006-5725.2018.21.025.
[36]	SHI H, HE H, OJHA SC, et al. Association of STAT3 and STAT4 polymorphisms with susceptibility to chronic hepatitis B virus infection and risk of hepatocellular carcinoma: a meta-analysis[J]. Biosci Rep, 2019, 39(6): BSR20190783. DOI: 10.1042/BSR20190783.
[37]	XIE J, ZHANG Y, ZHANG Q, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2369-2377. DOI: 10.1002/hep.26303.
[38]	YIN JP, YUE ZC, ZHUO SY. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. J Clin Hepatol, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054. 音金萍, 岳紫晨, 卓少元. STAT3: 慢性炎症介导肝癌进程的关键分子[J]. 临床肝胆病杂志, 2020, 36(4): 948-952. DOI: 10.3969/j.issn.1001-5256.2020.04.054.
[39]	FATEMIPOUR M, ARABZADEH S, MOLAEI H, et al. Evaluation of STAT3 rs1053004 single nucleotide polymorphism in patients with chronic hepatitis B and hepatocellular carcinoma[J]. Cell Mol Biol (Noisy-le-grand), 2017, 63(12): 45-50. DOI: 10.14715/cmb/2017.63.12.11.
[40]	LI M, LI F, LI N, et al. Association of polymorphism rs1053005 in STAT3 with chronic hepatitis B virus infection in Han Chinese population[J]. BMC Med Genet, 2018, 19(1): 52. DOI: 10.1186/s12881-018-0569-x.
[41]	ZHAO X, JIANG K, LIANG B, et al. STAT4 gene polymorphism and risk of chronic hepatitis B-induced hepatocellular carcinoma[J]. Cell Biochem Biophys, 2015, 71(1): 353-357. DOI: 10.1007/s12013-014-0205-0.
[42]	ZHANG L, XU K, LIU C, et al. Meta-analysis reveals an association between signal transducer and activator of transcription-4 polymorphism and hepatocellular carcinoma risk[J]. Hepatol Res, 2017, 47(4): 303-311. DOI: 10.1111/hepr.12733.
[43]	YANG Y, ZHENG B, HAN Q, et al. Targeting blockage of STAT3 inhibits hepatitis B virus-related hepatocellular carcinoma[J]. Cancer Biol Ther, 2016, 17(4): 449-456. DOI: 10.1080/15384047.2016.1156257.
[44]	WARIS G, HUH KW, SIDDIQUI A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress[J]. Mol Cell Biol, 2001, 21(22): 7721-7730. DOI: 10.1128/MCB.21.22.7721-7730.2001.
[45]	FANG Z, LI J, YU X, et al. Polarization of monocytic myeloid-derived suppressor cells by hepatitis b surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains the activation of T cells in chronic hepatitis B virus infection[J]. J Immunol, 2015, 195(10): 4873-4883. DOI: 10.4049/jimmunol.1501362.
[46]	MA Y, LI B, LI Y, et al. Expressions of HBx and ANGPTL4 in liver cancer tissues and their relationships with clinical pathology and prognosis[J]. Med & Pharm J Chin PLA, 2021, 256(10): 41-45. DOI: 10.3969/j.issn.2095-140X.2021.10.010. 马艳, 黎蓓, 李盈, 等. 肝癌组织HBx和ANGPTL4表达及与临床病理、预后的关系[J]. 解放军医药杂志, 2021, 256(10): 41-45. DOI: 10.3969/j.issn.2095-140X.2021.10.010.
[47]	GAN CJ, LI WF, LI CN, et al. EGF receptor inhibitors comprehensively suppress hepatitis B virus by downregulation of STAT3 phosphorylation[J]. Biochem Biophys Rep, 2020, 22: 100763. DOI: 10.1016/j.bbrep.2020.100763.
[48]	STIFTER SA, FENG CG. Interfering with immunity: detrimental role of type Ⅰ IFNs during infection[J]. J Immunol, 2015, 194(6): 2455-2465. DOI: 10.4049/jimmunol.1402794.
[49]	IVASHKIV LB, DONLIN LT. Regulation of type Ⅰ interferon responses[J]. Nat Rev Immunol, 2014, 14(1): 36-49. DOI: 10.1038/nri3581.
[50]	PAN J, ZHANG M, YAO TT, et al. Efficacy and influencing factors of interferon in the treatment of chronic hepatitis B aged 1~6 years[J]. Int J Virol, 2020, 3(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009. 潘静, 张敏, 姚甜甜, 等. 干扰素治疗1~6岁慢性乙型肝炎的疗效及影响因素[J]. 国际病毒学杂志, 2020, 3(3): 214-218. DOI: 10.3760/cma.j.issn.1673-4092.2020.03.009.
[51]	SADLER AJ, WILLIAMS BR. Interferon-inducible antiviral effectors[J]. Nat Rev Immunol, 2008, 8(7): 559-568. DOI: 10.1038/nri2314.
[52]	WANG WB, LEVY DE, LEE CK. STAT3 negatively regulates type Ⅰ IFN-mediated antiviral response[J]. J Immunol, 2011, 187(5): 2578-2585. DOI: 10.4049/jimmunol.1004128.
[53]	PENG YJ, YOU J, LI J, et al. Role of the JAK/STAT/SOCS signaling pathway in hepatitis B virus-related liver diseases[J]. J Clin Hepatol, 2021, 37(6): 1435-1439. DOI: 10.3969/j.issn.1001-5256.2021.06.045. 彭玉娟, 游晶, 李静, 等. JAK/STAT/SOCS信号通路在HBV相关肝脏疾病中的作用[J]. 临床肝胆病杂志, 2021, 37(6): 1435-1439. DOI: 10.3969/j.issn.1001-5256.2021.06.045.
[54]	TAI WT, CHENG AL, SHIAU CW, et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J]. J Hepatol, 2011, 55(5): 1041-1048. DOI: 10.1016/j.jhep.2011.01.047.
[55]	BLECHACZ BR, SMOOT RL, BRONK SF, et al. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2[J]. Hepatology, 2009, 50(6): 1861-1870. DOI: 10.1002/hep.23214.